Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates

TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-W...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 11; no. 11; p. 1682
Main Authors Awasthi, Mayanka, Macaluso, Anthony, Myscofski, Dawn, Prigge, Jon, Koide, Fusataka, Noyce, Ryan S., Fogarty, Siobhan, Stillwell, Helen, Goebel, Scott J., Daugherty, Bruce, Nasar, Farooq, Bavari, Sina, Lederman, Seth
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.11.2023
Subjects
Antibodies
Catheters
COVID-19
Cytokines
Dosage and administration
Effectiveness
Enzymes
horsepox virus
Immunogenetics
Immunogenicity
Immunoglobulin G
Infections
Laboratory animals
Lymphocytes T
Monkeys & apes
Primates
Proteins
Respiratory tract
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Smallpox vaccine
spike protein
Testing
TNX-1800
vaccine
vaccine platform
Vaccines
Viruses
γ-Interferon
United States
United States > US
Online AccessGet full text

Cover

Abstract TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.
AbstractList TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.
TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.
Audience Academic
Author Nasar, Farooq
Lederman, Seth
Koide, Fusataka
Noyce, Ryan S.
Goebel, Scott J.
Daugherty, Bruce
Bavari, Sina
Stillwell, Helen
Myscofski, Dawn
Prigge, Jon
Fogarty, Siobhan
Macaluso, Anthony
Awasthi, Mayanka
Author_xml – sequence: 1
  givenname: Mayanka
  orcidid: 0000-0002-4395-0589
  surname: Awasthi
  fullname: Awasthi, Mayanka
– sequence: 2
  givenname: Anthony
  surname: Macaluso
  fullname: Macaluso, Anthony
– sequence: 3
  givenname: Dawn
  surname: Myscofski
  fullname: Myscofski, Dawn
– sequence: 4
  givenname: Jon
  surname: Prigge
  fullname: Prigge, Jon
– sequence: 5
  givenname: Fusataka
  surname: Koide
  fullname: Koide, Fusataka
– sequence: 6
  givenname: Ryan S.
  orcidid: 0000-0002-9463-7314
  surname: Noyce
  fullname: Noyce, Ryan S.
– sequence: 7
  givenname: Siobhan
  surname: Fogarty
  fullname: Fogarty, Siobhan
– sequence: 8
  givenname: Helen
  surname: Stillwell
  fullname: Stillwell, Helen
– sequence: 9
  givenname: Scott J.
  surname: Goebel
  fullname: Goebel, Scott J.
– sequence: 10
  givenname: Bruce
  surname: Daugherty
  fullname: Daugherty, Bruce
– sequence: 11
  givenname: Farooq
  surname: Nasar
  fullname: Nasar, Farooq
– sequence: 12
  givenname: Sina
  surname: Bavari
  fullname: Bavari, Sina
– sequence: 13
  givenname: Seth
  orcidid: 0000-0003-2781-1455
  surname: Lederman
  fullname: Lederman, Seth
BookMark eNp1Uk1r2zAYNqODdV3vOwp22aHuJEvWxzGYdguErrRd6M3Ir6VUwZY6yw7Lr9hfnpKMfYTt1UHi5fnQA8_r7MQHb7LsLcGXlCr8YaMBnDeR7IbL4kV2WmDBc6ro48kf71fZeYxrnEYRKrk4zb7P-37yYWW8AzdukfYturLWgYYtChY93DzmRGJ8gWZo4TYGLd0wRXRnIPSN89qP6DZ82-yXy8MvUJVEXKtHc4H0SjsfR3Q_u7vPq7DMC1Q96a4zfmWQ8-gm-Kep1x7dDq5PjPgme2l1F835z_ss-3J99VB9yhefP86r2SIHJtSYWyEphwaXmmMiuaSNxcooEKSBxlIqwFLFKTWEQ1FK2RpImallstBCcEHPsvlBtw16XT_v3IdtHbSr94swrGo9jA46U6sGW9MSyUABKyXItpSNBYWxIawpy6T1_qD1PISvk4lj3bsIpuu0N2GKdSEVlYyVnCfouyPoOkyDT0n3KFoyzNhv1Eonf-dtGAcNO9F6JgSjQhRUJtTlP1DptKZ3kApiXdr_RcAHAgwhxsHYX7kJrnc9qo97lCj8iJJaokcXfPJy3f-JPwB3HM2o
CitedBy_id crossref_primary_10_1155_2024_9952803
crossref_primary_10_35825_2587_5728_2023_8_2_135_145
crossref_primary_10_1128_msphere_00265_24
Cites_doi 10.1016/S0140-6736(21)00306-8
10.1038/s41541-022-00503-y
10.1016/j.eclinm.2022.101624
10.1093/cid/ciac803
10.1002/iid3.946
10.1038/s41541-022-00436-6
10.2471/BLT.07.040089
10.1016/j.vaccine.2023.01.006
10.1038/s41586-020-2008-3
10.3390/v15020356
10.1101/2020.07.01.183236
10.1056/NEJMoa2022483
10.20944/preprints202305.0218.v1
10.1016/j.jmb.2023.168173
10.1016/j.ymthe.2021.10.008
10.1101/2023.09.06.556620
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
DOA
DOI 10.3390/vaccines11111682
DatabaseName CrossRef
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central
Engineering Research Database
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Open Access Full Text
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_9b0fed184c9c458c8d58bfc900e14b55
A774377238
10_3390_vaccines11111682
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GroupedDBID 53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
AAYXX
ABUWG
ADBBV
AEUYN
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
PMFND
3V.
7T7
7XB
8FD
8FK
C1K
FR3
MBDVC
P64
PKEHL
PQEST
PQGLB
PQUKI
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-c479t-f7836cb05a6018683bf09e9c71bcbf337cf39633e16c2588dec0093f482a77673
IEDL.DBID M48
ISSN 2076-393X
IngestDate Wed Aug 27 01:28:36 EDT 2025
Fri Jul 11 10:03:56 EDT 2025
Fri Jul 25 12:13:02 EDT 2025
Tue Jun 17 22:11:53 EDT 2025
Tue Jun 10 21:08:12 EDT 2025
Tue Jul 01 01:11:07 EDT 2025
Thu Apr 24 23:06:33 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License https://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c479t-f7836cb05a6018683bf09e9c71bcbf337cf39633e16c2588dec0093f482a77673
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9463-7314
0000-0002-4395-0589
0000-0003-2781-1455
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/vaccines11111682
PQID 2893354044
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_9b0fed184c9c458c8d58bfc900e14b55
proquest_miscellaneous_2893844566
proquest_journals_2893354044
gale_infotracmisc_A774377238
gale_infotracacademiconefile_A774377238
crossref_primary_10_3390_vaccines11111682
crossref_citationtrail_10_3390_vaccines11111682
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-11-01
PublicationDateYYYYMMDD 2023-11-01
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Vaccines (Basel)
PublicationYear 2023
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Jackson (ref_9) 2020; 383
Andre (ref_3) 2008; 86
ref_14
Tsuchiya (ref_11) 2023; 41
ref_12
ref_23
ref_22
ref_21
ref_20
Boulton (ref_15) 2022; 30
Travieso (ref_13) 2022; 7
Li (ref_17) 2023; 8
Notarte (ref_4) 2022; 53
Chiuppesi (ref_19) 2022; 7
Heath (ref_10) 2023; 76
ref_2
ref_18
Lotfi (ref_5) 2023; 11
ref_16
ref_8
Wu (ref_1) 2020; 579
ref_7
Wouters (ref_6) 2021; 397
References_xml – ident: ref_7
– volume: 397
  start-page: 1023
  year: 2021
  ident: ref_6
  article-title: Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00306-8
– volume: 7
  start-page: 1
  year: 2022
  ident: ref_13
  article-title: The use of viral vectors in vaccine development
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-022-00503-y
– ident: ref_8
– volume: 53
  start-page: 101624
  year: 2022
  ident: ref_4
  article-title: Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review
  publication-title: eClinicalMedicine
  doi: 10.1016/j.eclinm.2022.101624
– volume: 76
  start-page: 398
  year: 2023
  ident: ref_10
  article-title: Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
  publication-title: Clin. Infect Dis.
  doi: 10.1093/cid/ciac803
– ident: ref_2
– volume: 11
  start-page: e946
  year: 2023
  ident: ref_5
  article-title: Vaccination is the most effective and best way to avoid the disease of COVID-19
  publication-title: Immun. Inflamm. Dis.
  doi: 10.1002/iid3.946
– volume: 7
  start-page: 7
  year: 2022
  ident: ref_19
  article-title: Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-022-00436-6
– ident: ref_12
– volume: 86
  start-page: 140
  year: 2008
  ident: ref_3
  article-title: Vaccination greatly reduces disease, disability, death and inequity worldwide
  publication-title: Bull. World Health Organ.
  doi: 10.2471/BLT.07.040089
– volume: 41
  start-page: 1602
  year: 2023
  ident: ref_11
  article-title: Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2023.01.006
– volume: 579
  start-page: 265
  year: 2020
  ident: ref_1
  article-title: A new coronavirus associated with human respiratory disease in China
  publication-title: Nature
  doi: 10.1038/s41586-020-2008-3
– ident: ref_20
  doi: 10.3390/v15020356
– ident: ref_16
  doi: 10.1101/2020.07.01.183236
– volume: 383
  start-page: 1920
  year: 2020
  ident: ref_9
  article-title: An mRNA Vaccine against SARS-CoV-2–Preliminary Report
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2022483
– ident: ref_18
  doi: 10.20944/preprints202305.0218.v1
– ident: ref_22
– ident: ref_23
– ident: ref_14
  doi: 10.1016/j.jmb.2023.168173
– volume: 30
  start-page: 1885
  year: 2022
  ident: ref_15
  article-title: Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2021.10.008
– volume: 8
  start-page: 1
  year: 2023
  ident: ref_17
  article-title: Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus
  publication-title: Signal Transduct. Target. Ther.
– ident: ref_21
  doi: 10.1101/2023.09.06.556620
SSID ssj0000913867
Score 2.269767
Snippet TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The...
SourceID doaj
proquest
gale
crossref
SourceType Open Website
Aggregation Database
Enrichment Source
Index Database
StartPage 1682
SubjectTerms Antibodies
Catheters
COVID-19
Cytokines
Dosage and administration
Effectiveness
Enzymes
horsepox virus
Immunogenetics
Immunogenicity
Immunoglobulin G
Infections
Laboratory animals
Lymphocytes T
Monkeys & apes
Primates
Proteins
Respiratory tract
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Smallpox vaccine
spike protein
Testing
TNX-1800
vaccine
vaccine platform
Vaccines
Viruses
γ-Interferon
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Rb9MwELbQnnhBMEAEBjokNIRUq4ntJM5jqTYNBFXFuqpvke04qBIkaG2n7Vfwl7mL025FAl54TGxLdu58953j-46xN2jwlEA3wkUqY64Q8vMC_TynklZGKKtll_X-eZKdXaiPi3Rxp9QX3QkL9MDhww0LG9e-wjjEFU6l2ukq1bZ2RRz7RNm0Yy9Fn3cnmOpscJFIneXhv6TEuH54ZRz9qV6RiUgyLfb8UEfX_yej3Hma04fsQQ8RYRSm9ojd880hO54GjumbAcxuU6ZWAziG6S379M1j9vMDZXy0qBdLhwgbTFPBCfFE4Fhoa5hNFjxB_DaAEXxCUwfz5eVmBRSGfrfdtRiYttdX3ct5WA2MKfeFjgYGYL6aJSJKOB99Oefjds4FjLf1WGDZwKRturJ_MCUaC8SxT9jF6clsfMb7qgvcqbxY85ryOpyNU4OC05mWto4LX7g8sc7WUuaulrhrpU8yJ1KtK-_oWKRWWhiiBpJP2UHTNv4ZAym8LiovRGVRfqZCwRl8lqbOfGq1i9hwK4PS9ZTkVBnjW4mhCUmt_F1qEXu3G_Ej0HH8pe97EuuuHxFpdy9Qvcpevcp_qVfE3pJSlLTdcWooq5C1gAsk4qxyhPBZ5lS5LWJHez1xm7r95q1alb2ZWJUY7Uo6eFMqYq93zTSSrr41vt2EPlohzs2e_48FvWD3BeK0kE55xA7Wlxv_EnHV2r7qttAvQgYfqA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swEBZb-rKXsZ8sWzduMDoGEbEl2ZafRhpSurEF06Yhb8aS5RLY7C5OyvpX7F_ene0kZLA-2paMzelOn06672PsAwY8JXAa4SKQHlcI-XmM8zwnSatMKKNlU_X-fRqeX6mvi2DRJdzq7ljlNiY2gTqvLOXIh4J04RFeKPX55hcn1SjaXe0kNB6yIwzBWvfY0elkmlzssizEeqnDqN2flLi-H95mlnasawoVfqjFwXzU0Pb_Lzg3M87ZE_a4g4owam37lD1w5TN2krRc03cDmO1Lp-oBnECyZ6G-e87-fKHKjwrHx9Ii0oaszGFCfBHYF6oCZtMF9xHHDWAE3zDkwXy52tRAy9GfpjkeA0n1-7a5OW__BsZUA0MpggFk19kSkSVcji4u-biacwHjrS4LLEuYVmUj_wcJ0Vkgnn3Brs4ms_E579QXuFVRvOYF1XdY4wUZGlCHWprCi11sI99YU0gZ2UKi90rnh1YEWufOUnqkUFpkRBEkX7JeWZXuFQMpnI5zJ0RutLJZrk2R4bXMitAFRts-G25tkNqOmpwUMn6kuEQhq6X_Wq3PPu163LS0HPe0PSWz7toRoXZzo1pdp51_prHxCpfjctfGVgXa6jzAr7Sx5zlfmSDos480KFJye_w0tFVbvYA_SARa6QhhtIxIwa3Pjg9aorvaw8fbYZV24aJO94O7z97vHlNPOgJXumrTttEK8W74-v5XvGGPBCKxtmDymPXWq417i8hpbd517vEXp3EYAA
  priority: 102
  providerName: ProQuest
Title Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
URI https://www.proquest.com/docview/2893354044
https://www.proquest.com/docview/2893844566
https://doaj.org/article/9b0fed184c9c458c8d58bfc900e14b55
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBejfdnL2Cfz1gUNRscgWm1JtuWHMdKQ0o01mDYJeTOWLJdAZ2_5KM1fsX95d7KTkNEN9mhbMpZPd_c7Sfc7Qt6BwZMc3AjjofCZBMjPEvDzDEta5VxqJVzW-8UwOh_Lr9NwukuPbn_g4t7QDutJjec3H-9-rj-Dwn_CiBNC9pPb3OAm9AK1P4gUGORD8Esx1jO4aMG-s8tJIJQrKcsheGciEdNm3_Lel-z5KUfn_zej7TzR2WPyqIWQtNfI_Al5YKun5DhtOKjXXTrapVQtuvSYpjt26vUz8usLZoTUMG9mBhA4zauCDpBHAvrSuqSj4ZQFgO-6tEe_gSmkk9l8taAYpn7X7tgMTeu7W3dz0oyG9jE3BpcOujS_zmeAOOlV7_KK9esJ47S_qddCZxUd1pUrC0hTpLkAnPucjM8Go_45a6syMCPjZMlKzPsw2g9zEKyKlNCln9jExIE2uhQiNqUArRY2iAwPlSqswWWTUiqeI3WQeEEOqrqyLwkV3KqksJwXWkmTF0qXOVyLvIxsqJXxyMlGBplpKcuxcsZNBqELSi37U2oe-bDt8aOh6_hH21MU67YdEm27G_X8Omv1Nku0X9oCwmCTGBkqo4oQvtIkvm8DqcPQI-9xUmQ4QeHTQFZNVgMMEIm1sh7AaxFjZTePHO21BDU2-4830yrbaEEG0bDAhTkpPfJ2-xh74tG4ytarpo2SgIOjV_8x-NfkIQe41mRVHpGD5Xxl3wC8WuoOOTwdDNPLjlue6Dgd-g2zVSO5
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdG9wAviE8RGGAkGEKq1dR2UucBoa50allXVVtX9S3EjjNVgmT0Y9C_gv-Ev5G7fLQqEnvbYxI7snXnu9_ZvvsR8hYMnuTgRhj3hMskQH4WgJ9nSGkVcamVyLPeT4d-70J-mXrTPfKnyoXBa5WVTcwNdZwZ3CNvcOSFB3gh5aerHwxZo_B0taLQKNTixK5_Qsi2-Nj_DPJ9x_lxd9zpsZJVgBnZCpYswbwFo10vgoEpXwmduIENTKupjU6EaJlEgFYK2_QN95SKrcGwP5GKR1j6RsB_75B9KXyX18j-UXc4Otvs6mCVTeW3ivNQIQK3cR0ZPCFfoGlq-orv-L-cJuB_ziD3cMcPyP0SmtJ2oUsPyZ5NH5HDUVHbel2n422q1qJOD-loW_V6_Zj87mOmSQb6ODOA7GmUxrSL9SmgL80SOh5OWRNwY5226QBMLJ3M5qsFxfD3u86v49BR9us6fzkpZkM7mHODWxJ1Gl1GM0Cy9Lx9ds462YRx2ql4YOgspcMszekG6QjLZwB-fkIubkUuT0ktzVL7jFDBrQpiy3mslTRRrHQSwbOIEt96WhmHNCoZhKYshY6MHN9CCIlQauG_UnPIh02Pq6IMyA1tj1Csm3ZYwDt_kc0vw9IehIF2ExtDeG0CIz1lVOzBKE3gurYptec55D0qRYhmBoYGsiqyJWCCWLArbANsFy1kjHPIwU5LMA9m93OlVmFpnhbhdjE55M3mM_bEK3epzVZFGyUBX_vPb_7Fa3K3Nz4dhIP-8OQFuccBBRbJmgektpyv7EtAbUv9qlwqlHy97dX5FxtRU8E
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJyG-IF5FYYCRYAipVlPbSZwPCHVdq5WNKtq6qd9C7DhTJUhGXwb9Ffwffh13eWlVJPZtH5PYka073z1n-54j5C0YPMnBjTDuCodJgPwsAD_PsKRVzKVWosh6_zLyjs7l54k72SF_6lwYvFZZ28TCUCe5wT3yNse68AAvpGyn1bWI8HDw6eoHwwpSeNJal9MoVeTYrn5C-Db_ODwEWb_jfNAf945YVWGAGekHC5ZiDoPRjhvDIJWnhE6dwAbG72ijUyF8kwrQUGE7nuGuUok1uAWQSsVjpMER8N87ZNfHqKhBdg_6o_B0vcODjJvK88uzUSECp30dGzwtn6OZ6niKb_nComTA_xxD4e0GD8j9CqbSbqlXD8mOzR6R_bDkuV616HiTtjVv0X0abhiwV4_J7yFmneSgm1MDKJ_GWUL7yFUBfWme0vFowjqAIVu0S0_A3NKL6Ww5pxgKf9fF1Rwa5r-ui5cX5WxoD_NvcHuiRePLeAqolp51T89YL79gnPbqmjB0mtFRnhWlB2mIVBqApZ-Q81uRy1PSyPLMPiNUcKuCxHKeaCVNnCidxvAs4tSzrlamSdq1DCJT0aJjdY5vEYRHKLXoX6k1yYd1j6uSEuSGtgco1nU7JPMuXuSzy6iyDVGgndQmEGqbwEhXGZW4MEoTOI7tSO26TfIelSJCkwNDA1mVmRMwQSTviroA4YWP1eOaZG-rJZgKs_25VquoMlXzaLOwmuTN-jP2xOt3mc2XZRslAWt7z2_-xWtyF1ZldDIcHb8g9zgAwjJvc480FrOlfQkAbqFfVSuFkq-3vTj_AuPZV_Y
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunogenicity+and+Efficacy+of+TNX-1800%2C+A+Live+Virus+Recombinant+Poxvirus+Vaccine+Candidate%2C+against+SARS-CoV-2+Challenge+in+Nonhuman+Primates&rft.jtitle=Vaccines+%28Basel%29&rft.au=Awasthi%2C+Mayanka&rft.au=Macaluso%2C+Anthony&rft.au=Myscofski%2C+Dawn&rft.au=Prigge%2C+Jon&rft.date=2023-11-01&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=11&rft.issue=11&rft.spage=1682&rft_id=info:doi/10.3390%2Fvaccines11111682&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines11111682
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon